§ 03 · FREQUENTLY ASKED
The questions this domain attracts — answered without the hedge.
Regulation, research, pharmacokinetics, and why 'can I get a script?' is a more interesting question than it first appears.
What is BPC-157 and where does it come from?
BPC-157 is a 15-amino-acid synthetic peptide whose sequence is derived from a partial region of human gastric body protection compound protein — a protein found in human gastric juice. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and the compound has a molecular weight of 1,419.5 daltons. It was originally identified and studied by a Croatian pharmaceutical research group at the University of Zagreb beginning in the 1990s, and entered a pharmaceutical development program under the clinical designation PL-14736. No pharmaceutical-grade licensed drug has resulted from that development program.
Why is BPC-157 sometimes called 'gastric pentadecapeptide'?
'Pentadecapeptide' simply means a peptide of 15 amino acids — 'penta' (five) plus 'deca' (ten). 'Gastric' refers to its origin: the sequence is derived from a gastric juice protein. You will see 'stable gastric pentadecapeptide BPC 157' in many paper titles from the Zagreb group; this phrasing emphasizes the compound's unusual stability in the gastric environment, which distinguishes it from most peptides of similar size. Research databases also index it as PL 14736, PL-10, and BPC 157 acetate depending on the salt form used.
Is BPC-157 a natural compound or synthetic?
It is synthetic. The sequence was identified in a naturally occurring protein (human gastric body protection compound), but BPC-157 itself is a synthetic peptide manufactured by solid-phase peptide synthesis. The commercially available research chemical forms are BPC-157 acetate and BPC-157 free base; these are different salt forms of the same peptide. No natural food source or human biochemical process produces the isolated 15-amino-acid sequence in bioavailable quantities.
What does 'stable in gastric juice' actually mean for research purposes?
Most peptides above a few hundred daltons degrade rapidly when exposed to gastric acid and pepsin. BPC-157 maintains its structural integrity in human gastric juice for more than 24 hours [1]. This stability is what makes oral and intragastric dosing routes plausible in rodent studies — the peptide survives the gastric environment long enough to be absorbed downstream. Whether this translates to sufficient oral bioavailability in humans to produce pharmacological effects is a question the cancelled Phase I pharmacokinetics trial (NCT02637284) would have addressed. The gastric stability is a pharmacological property, not a claim of human efficacy.
What does current research show about BPC-157 for tissue healing?
The preclinical literature — primarily in rat models — consistently documents accelerated healing of tendon, ligament, muscle, and bone injuries. In rats with surgically detached quadriceps muscles, oral BPC-157 enabled complete muscle-to-bone reattachment confirmed by MRI by day 28; saline controls showed permanent healing failure [5]. In ligament healing studies, both 10 μg/kg and 10 ng/kg intraperitoneal daily doses improved biomechanical tensile strength and collagen organization through 90 days [6]. A 2025 systematic review of 36 studies confirmed consistent functional and structural improvements across these tissue types [4]. Human data consists of three small uncontrolled pilot studies with no randomized comparator — the direction of findings is encouraging; the evidence quality does not yet support clinical conclusions.
What human clinical data exists for BPC-157?
Three small human pilot studies have been published. First: a retrospective series of 12 patients with chronic knee pain receiving intra-articular BPC-157 injections; 7 of 12 reported pain relief lasting more than 6 months [4]. Second: a 12-patient pilot for interstitial cystitis; all 12 reported 80–100% symptom resolution at 6 weeks after intravesicular injection of 10 mg, and all had previously failed FDA-approved pentosan polysulfate [2]. Third: an IRB-approved (IRCM-2024-402) intravenous safety and pharmacokinetics study in 2 healthy adults who received up to 20 mg IV infusion with no adverse events and no clinically meaningful changes in cardiovascular, hepatic, renal, thyroid, or metabolic biomarkers [2]. A Croatian Phase II trial for inflammatory bowel disease (PL-14736) was conducted with rectal administration and reported as safe, but results were not published in peer-reviewed form [3]. No randomized controlled trial exists.
Why does most BPC-157 research come from one group in Zagreb?
The BPC-157 literature is heavily concentrated in publications from Predrag Sikiric, Sven Seiwerth, and their colleagues at the University of Zagreb. This is partly historical — the group did the foundational work beginning in the late 1980s and 1990s, established the animal models, and has published continuously since. It also reflects a common pattern in research on compounds with limited commercial backing: when there is no major pharmaceutical company funding independent replication, the original group often remains the primary publisher. Independent analysis exists — the 2025 systematic reviews by McGuire et al. and Vasireddi et al. were conducted by authors at US academic medical centers — but they analyzed the Zagreb-group data rather than generating new primary data. Whether future independent replication confirms the Zagreb findings is the central open question in the field.
How long does BPC-157 stay in the body?
The pharmacokinetic study by He et al. established a plasma half-life under 30 minutes in both rat and beagle dog models following IV and IM administration. Tmax was 3 minutes in rats and 6.3–8.7 minutes in dogs. Intramuscular bioavailability was 14–19% in rats and 45–51% in dogs. The compound is metabolized hepatically to proline and small peptide fragments, with approximately 16–18% urinary recovery [1]. The sub-30-minute half-life is notable because preclinical studies have documented functional effects sustained for weeks to months after single or short-course treatment. The mechanism that reconciles rapid plasma clearance with durable preclinical effects is not definitively established in the published literature.
What is BPC-157's regulatory and compounding status in the United States as of 2026?
BPC-157 has no FDA drug approval; prescription access and compounding eligibility are separate questions. It is not on FDA’s 503A bulks list, which addresses ingredient eligibility under that compounding framework. FDA now records BPC-157 under “nominated but withdrawn,” with safety concerns still published beside the entry (FDA). Withdrawal of a nomination does not establish permission to compound or a Category 1 placement. Compounded medications are not FDA-approved. The Pharmacy Compounding Advisory Committee (PCAC) discussed BPC-157 free base and acetate as 503A bulks-list candidates in July 2026; committee advice does not constitute a final FDA listing decision (FDA meeting notice).
Is BPC-157 available by prescription?
A request does not guarantee a prescription: a licensed provider must review it and decide. The prescription service at Promise Peptides (mypromise.com) now includes BPC-157, with licensed U.S. providers making the prescribing decision; not everyone qualifies. Care is limited to U.S. patients, with availability differing by state and treatment. Compounded medications are not FDA-approved. FDA’s withdrawn-nomination entry does not establish permission to compound; its safety concerns remain (FDA).
What are the legitimate research pathways to investigate BPC-157 in humans?
Three FDA-recognized pathways exist for human investigation of unapproved compounds. First, an Investigational New Drug (IND) application, which allows clinical trials under FDA and IRB oversight — this is the standard path for drug development. Second, an Expanded Access (Compassionate Use) IND for patients with serious conditions lacking alternatives, which also requires FDA approval and a sponsor/manufacturer supply chain. Third, IRB-approved observational or safety pilot studies — the framework under which Lee and Burgess conducted the 2025 IV safety and pharmacokinetics study (IRCM-2024-402) in 2 healthy adults [2]. ClinicalTrials.gov registration (NCT02637284) was attempted for a Phase I pharmacokinetics study in 2015, but that trial was cancelled in 2016 before completion [3].
What is the difference between 503A compounding and investigational use of BPC-157?
503A compounding pharmacies prepare customized medications for individual patients based on a valid prescription. A 503A prescription does not by itself settle whether an ingredient is eligible under the compounding rules. Investigational use, by contrast, occurs under an IND application submitted to the FDA; it is not prescription-based and requires IRB oversight and FDA authorization. Prescription review and IND research authorization answer separate questions; neither establishes FDA drug approval for BPC-157. The July 2026 PCAC meeting was an advisory discussion about possible bulks-list inclusion (FDA meeting notice).
What does withdrawal from FDA's Category 2 table mean?
BPC-157 previously appeared in Category 2 and now sits in FDA’s withdrawn-nomination table. That table records a nomination withdrawal, with the safety concerns still published (FDA). The withdrawal is a procedural status, not a finding that BPC-157 is safe or eligible for compounding. A withdrawn nomination does not authorize compounding, and BPC-157 remains without FDA drug approval. The PCAC discussed BPC-157 free base and acetate as 503A bulks-list candidates in July 2026 (FDA meeting notice). Committee advice cannot substitute for FDA rulemaking.
Why is BPC-157 banned by WADA and what does that mean for athletes?
The World Anti-Doping Agency placed BPC-157 on the Prohibited List under Section S0 — Non-Approved Substances, effective January 1, 2022. S0 prohibits any pharmacological substance not approved by a regulatory authority for human therapeutic use, regardless of whether it is a performance-enhancing agent in the conventional sense. BPC-157 is prohibited at all times in all sports under the WADA Code. Competitive athletes subject to WADA rules who are detected using BPC-157 face the standard anti-doping sanctions regardless of therapeutic intent or whether the use was supervised by a physician. The WADA ban does not reflect a determination that BPC-157 enhances athletic performance; it reflects the general prohibition on non-approved substances.
What enforcement actions have occurred related to BPC-157?
One compounding enforcement case involved distribution of BPC-157 and related unapproved peptides. The case resulted in a $1.79 million forfeiture and served as an industry-wide enforcement signal to compounding pharmacies. The case concerned unapproved drug distribution; BPC-157’s withdrawal from the Category 2 table does not give it FDA drug approval. FDA still records safety concerns for BPC-157 in its withdrawn-nomination entry (FDA).
How does the 503A bulks list relate to a prescription?
FDA’s 503A bulks list addresses which ingredients may be used under that compounding framework. Ingredient eligibility and FDA approval of a finished drug are separate questions. An individual prescription does not change either regulatory status. The advisory committee offers recommendations; FDA makes final listing decisions through rulemaking.